Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Runben Biotechnology CoSHSE:603193 -1.79%72 Current Ratio is 10.98 as of Mar. 2026, which is 13% above its 10-year median of 9.71. GuruFocus rates SHSE:603193 with a GF Score™ of 72/100 and a GF Value™ of ¥28.24 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,994 Consumer Packaged Goods companies, Runben Biotechnology Co ranks better than 96.64% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Runben Biotechnology Co's current ratio for the quarter that ended in Mar. 2026 was 10.98.
Runben Biotechnology Co has a current ratio of 10.98. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Runben Biotechnology Co's Current Ratio or its related term are showing as below:
SHSE:603193'
s Current Ratio Range Over the Past 10 Years
Min: 2.92 Med: 9.71 Max: 18.04
Current: 10.98
During the past 7 years, Runben Biotechnology Co's highest Current Ratio was 18.04. The lowest was 2.92. And the median was 9.71.
SHSE:603193's Current Ratio is ranked better than 96.64% of 1994
companies
in the Consumer Packaged Goods industry
Industry Median: 1.73
vs SHSE:603193: 10.98
Runben Biotechnology Co (SHSE:603193) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Runben Biotechnology Co Current Ratio Related Terms
Runben Biotechnology Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603193 vs PG, CL, KVUE: Current Ratio Comparison
For the Household & Personal Products subindustry, Runben Biotechnology Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Runben Biotechnology Co Current Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Runben Biotechnology Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Runben Biotechnology Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Runben Biotechnology Co (SHSE:603193) has a Current Ratio of 10.98 as of Mar. 2026. This is 13% above median its historical median of 9.71. Over the past decade, Runben Biotechnology Co's Current Ratio has ranged from 2.92 to 18.04. According to the industry distribution chart, Runben Biotechnology Co ranks #67 out of 1994 companies in the Consumer Packaged Goods industry, placing it in the top 3.4%.
Is Runben Biotechnology Co's Current Ratio too high?
Runben Biotechnology Co's current Current Ratio of 10.98 is 13% above median its 10-year median of 9.71. Over the past 10 years, this metric has ranged from a low of 2.92 to a high of 18.04. The Consumer Packaged Goods industry median Current Ratio is 1.73. Runben Biotechnology Co's value of 10.98 is 534.7% above this industry median. Based on the distribution chart, Runben Biotechnology Co ranks #67 out of 1994 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Runben Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Runben Biotechnology Co's Current Ratio compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Runben Biotechnology Co ranks #67 out of 1994 companies for Current Ratio. This places Runben Biotechnology Co in the top 3% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.73. Runben Biotechnology Co's value of 10.98 is 534.7% above this benchmark. Historically, Runben Biotechnology Co's own Current Ratio has ranged from 2.92 to 18.04 over the past decade. While the company's 10-year median is 9.71 vs. the industry median of 1.73, Runben Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Consumer Packaged Goods company?
The median Current Ratio among Consumer Packaged Goods companies is 1.73, based on 1,994 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Runben Biotechnology Co's current Current Ratio of 10.98 is 534.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median Current Ratio is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Runben Biotechnology Co's current Current Ratio is 10.98, which is 13% above median its own 10-year median of 9.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Runben Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Runben Biotechnology Co (SHSE:603193) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥28.24, compared to a current price of ¥21.96 — trading 22.2% below its estimated fair value. The current Current Ratio is 10.98, which is 13% above median its 10-year median of 9.71 and 534.7% above the Consumer Packaged Goods industry median of 1.73. Runben Biotechnology Co's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Runben Biotechnology Co (SHSE:603193), the current Current Ratio is 10.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Runben Biotechnology Co (SHSE:603193) Overvalued in 2026?
Based on GuruFocus' analysis, Runben Biotechnology Co stock appears to be undervalued.
The current stock price of ¥21.96 is trading 22.2% below its estimated GF Value™ of ¥28.24.
GuruFocus considers Runben Biotechnology Co to be Modestly Undervalued.
Key valuation signals for SHSE:603193:
Current Ratio: 10.98 (13% above median its 10-year median of 9.71)
GF Value™: ¥28.24 vs. price of ¥21.96 (22.2% below fair value)
Industry Position: 534.7% above the Consumer Packaged Goods median (#67 of 1994)
No single metric tells the full story. See the SHSE:603193 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603193 has been successfully added to your 
